Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the ELSS median (51 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 02 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Bank of India ELSS Tax Saver |
|---|---|
| 02 Jan 2013 | ₹100.00 |
| 21 Feb 2014 | ₹109.28 |
| 12 Apr 2015 | ₹174.34 |
| 31 May 2016 | ₹163.11 |
| 19 Jul 2017 | ₹216.68 |
| 07 Sep 2018 | ₹253.83 |
| 27 Oct 2019 | ₹248.09 |
| 15 Dec 2020 | ₹331.62 |
| 03 Feb 2022 | ₹475.19 |
| 25 Mar 2023 | ₹458.30 |
| 12 May 2024 | ₹751.40 |
| 01 Jul 2025 | ₹805.79 |
| 20 Aug 2026 | ₹842.72 |
| Metric | Bank of India · Direct NAV ₹198.04 Very High risk ★★★☆☆ | Category median ELSS · 51 funds |
|---|---|---|
| +7.33% | +3.05% | |
| +15.38% | +14.46% | |
| +13.21% | +13.60% | |
| +16.70% | +13.74% | |
| +16.93% | +14.97% | |
| +13.02% | — | |
| +18.24% | +16.84% | |
| +18.20% | +17.15% | |
| +18.03% | +15.41% | |
| Risk | ||
| 17.42% | 14.19% | |
| 0.51 | 0.52 | |
| 0.67 | 0.70 | |
| -31.69% | -35.94% | |
| Nifty 500 | — | |
| +2.92% | +1.57% | |
| 1.07 | 0.97 | |
| 116.3% | 102.3% | |
| 107.9% | 93.6% | |
| 1.06% | 1.06% | |
| ₹1,383Cr | ₹765.87Cr | |
| None | — | |
| 3 years | — | |
| ₹500 | — | |
| ₹500 | — | |
| 31% | 34% | |
| Alok Singh · 4.3y | — | |
| 02 Jan 2013 | — | |
| 56 | — | |
| 33.1% | — | |
| 7.2% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.